|
US 12,338,230 B2 |
|
| Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| Jason Allan Wiles, Madison, CT (US); Avinash S. Phadke, Branford, CT (US); Milind Deshpande, Madison, CT (US); Atul Agarwal, Hamden, CT (US); Dawei Chen, Guilford, CT (US); Venkat Rao Gadhachanda, Hamden, CT (US); Akihiro Hashimoto, Branford, CT (US); Godwin Pais, Hamden, CT (US); Qiuping Wang, Bethany, CT (US); Xiangzhu Wang, Branford, CT (US); and William Greenlee, Teaneck, NJ (US) |
| Assigned to Achillion Pharmaceuticals, Inc., Boston, MA (US) |
| Filed by Achillion Pharmaceuticals, Inc., Boston, MA (US) |
| Filed on Jan. 22, 2024, as Appl. No. 18/418,560. |
| Application 18/418,560 is a continuation of application No. 17/835,098, filed on Jun. 8, 2022, granted, now 11,926,617. |
| Application 17/835,098 is a continuation of application No. 16/867,475, filed on May 5, 2020, granted, now 11,407,738, issued on Aug. 9, 2022. |
| Application 16/867,475 is a continuation of application No. 15/905,524, filed on Feb. 26, 2018, granted, now 10,662,175, issued on May 26, 2020. |
| Application 15/905,524 is a continuation of application No. PCT/US2016/048788, filed on Aug. 25, 2016. |
| Claims priority of provisional application 62/210,116, filed on Aug. 26, 2015. |
| Prior Publication US 2024/0199583 A1, Jun. 20, 2024 |
| Int. Cl. C07D 407/14 (2006.01); A61P 1/16 (2006.01); A61P 29/00 (2006.01); A61P 37/00 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/10 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/22 (2006.01); C07D 493/04 (2006.01); C07D 513/04 (2006.01); C07D 519/00 (2006.01); C07F 9/6558 (2006.01) |
